NRD
TGTX icon

Nebula Research & Development’s TG Therapeutics TGTX Stock Holding History

Nebula Research & Development’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-39,146
Closed -$327K – 872
2023
Q3 		$327K Buy
+39,146
New +$546K 0.17% 251

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Nebula Research & Development's TGTX Position: Q4 2023 in Review

Nebula Research & Development sold out of TG Therapeutics (TGTX) in Q4 2023, closing a stake of 39,146 shares — an estimated $327K sold.

Nebula Research & Development first reported a position in TGTX in Q3 2023 and held it in 1 quarter. The position peaked at $327K in Q3 2023. 235 funds tracked by Wall St. Rank hold TGTX as of Q4 2023.

  • Nebula Research & Development reported no remaining TG Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Nebula Research & Development sold 39,146 TG Therapeutics shares in Q4 2023, an estimated $327K.
  • Nebula Research & Development first reported a position in TG Therapeutics in Q3 2023 and held it in 1 quarter.
  • Nebula Research & Development's TG Therapeutics position peaked at $327K in Q3 2023.
  • 235 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2023.

Based on Nebula Research & Development's 13F filing for Q4 2023, filed 14 Feb 2024.